Sarcoma  >>  capecitabine  >>  Phase 2
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
capecitabine / Generic mfg.
NCT00954876: Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer

Withdrawn
2
0
US
capecitabine and cetuximab
Translational Genomics Research Institute, Eli Lilly and Company
Metastatic Colorectal Cancer
01/10
01/10
NCT00496587: Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma

Completed
2
34
US
Capecitabine, Xeloda, Gemcitabine, Gemzar, Gemcitabine Hydrochloride, Bevacizumab, Avastin, Anti-VEGF monoclonal antibody, rhuMAb-VEGF
M.D. Anderson Cancer Center, Eli Lilly and Company
Renal Cell Carcinoma, Kidney Cancer
05/16
05/16
NCT00780494: Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma

Checkmark ASCO-GI 2014
Jan 2014 - Jan 2014: ASCO-GI 2014
Completed
2
35
US
bevacizumab, Avastin, carboplatin, Paraplatin, capecitabine, Xeloda
Pamela L. Kunz, Genentech, Inc.
Stomach Cancer, Gastric (Stomach) Cancer, Neoplasm of Cardioesophageal Junction, Gastrointestinal Stromal Tumor (GIST)
12/17
12/17
Pan-MSI-ACSE, NCT06333314: Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI

Not yet recruiting
2
120
Europe
Dostarlimab, Chemotherapy
UNICANCER, National Cancer Institute, France, GlaxoSmithKline
Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma, Neuroendocrine Carcinoma, Soft Tissue Sarcoma, Small Bowel Adenocarcinoma, Duodenum Adenocarcinoma, Gastric Adenocarcinoma
10/28
09/30
NCT03009058 / 2016-001459-28: Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer

Terminated
1/2
2
Europe
IMM-101, Heat killed M. obuense (NCTC) 13365), Gemcitabine, GEMZAR, Nabpaclitaxel, Abraxane, Capecitabine, Folinic Acid, Leucovorin, Fluorouracil, 5FU, Irinotecan, Campto, Camptosar, Oxaliplatin, Eloxatin, cetuximab, Erbitux, Anti-PD1, pembrolizumab (KEYTRUDA),, nivolumab (OPDIVO), Ipilimumab, YERVOY, Cyclophosphamide, cytophosphane
Immodulon Therapeutics Ltd
Metastatic Cancer
08/17
08/17
NCT03997968: A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Active, not recruiting
1/2
170
US
CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine, CYT-0851 in combination with rituximab and bendamustine
Cyteir Therapeutics, Inc.
Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
07/24
12/24

Download Options